vs
Side-by-side financial comparison of BGSF, INC. (BGSF) and CHAMPIONS ONCOLOGY, INC. (CSBR). Click either name above to swap in a different company.
BGSF, INC. is the larger business by last-quarter revenue ($22.0M vs $15.0M, roughly 1.5× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -5.3%, a 7.0% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -9.4%). BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -5.3%).
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
BGSF vs CSBR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $22.0M | $15.0M |
| Net Profit | $-1.2M | $268.0K |
| Gross Margin | 35.0% | 51.7% |
| Operating Margin | -17.6% | 1.2% |
| Net Margin | -5.3% | 1.8% |
| Revenue YoY | -9.4% | 11.5% |
| Net Profit YoY | -18.2% | -63.2% |
| EPS (diluted) | $-0.12 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.0M | $15.0M | ||
| Q3 25 | $26.9M | $14.0M | ||
| Q2 25 | $23.5M | $12.4M | ||
| Q1 25 | $20.9M | $17.0M | ||
| Q4 24 | $24.3M | $13.5M | ||
| Q3 24 | $29.8M | $14.1M | ||
| Q2 24 | $25.7M | $14.0M | ||
| Q1 24 | $24.5M | $12.0M |
| Q4 25 | $-1.2M | $268.0K | ||
| Q3 25 | $-5.8M | $-436.0K | ||
| Q2 25 | $-3.7M | $-1.8M | ||
| Q1 25 | $-722.0K | $4.5M | ||
| Q4 24 | $-981.0K | $728.0K | ||
| Q3 24 | $-804.0K | $1.3M | ||
| Q2 24 | $-761.0K | $-109.0K | ||
| Q1 24 | $-792.0K | $-2.5M |
| Q4 25 | 35.0% | 51.7% | ||
| Q3 25 | 35.9% | 42.9% | ||
| Q2 25 | 35.8% | 41.1% | ||
| Q1 25 | 36.2% | 61.2% | ||
| Q4 24 | 35.9% | 44.9% | ||
| Q3 24 | 35.9% | 49.7% | ||
| Q2 24 | 37.3% | 48.2% | ||
| Q1 24 | 38.1% | 34.7% |
| Q4 25 | -17.6% | 1.2% | ||
| Q3 25 | -3.5% | -3.8% | ||
| Q2 25 | -18.8% | -16.2% | ||
| Q1 25 | 1.6% | 26.4% | ||
| Q4 24 | -15.7% | 5.4% | ||
| Q3 24 | -3.4% | 9.5% | ||
| Q2 24 | -5.7% | -1.9% | ||
| Q1 24 | 1.7% | -21.4% |
| Q4 25 | -5.3% | 1.8% | ||
| Q3 25 | -21.6% | -3.1% | ||
| Q2 25 | -15.9% | -14.9% | ||
| Q1 25 | -3.5% | 26.4% | ||
| Q4 24 | -4.0% | 5.4% | ||
| Q3 24 | -2.7% | 9.3% | ||
| Q2 24 | -3.0% | -0.8% | ||
| Q1 24 | -3.2% | -21.1% |
| Q4 25 | $-0.12 | $0.02 | ||
| Q3 25 | $-0.52 | $-0.03 | ||
| Q2 25 | $-0.34 | $-0.12 | ||
| Q1 25 | $-0.06 | $0.31 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | $-0.07 | $0.09 | ||
| Q2 24 | $-0.07 | $-0.01 | ||
| Q1 24 | — | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $8.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $4.2M |
| Total Assets | $57.8M | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.5M | ||
| Q3 25 | $41.2M | $10.3M | ||
| Q2 25 | $2.8M | $9.8M | ||
| Q1 25 | $2.0M | $3.2M | ||
| Q4 24 | $32.0K | $2.8M | ||
| Q3 24 | $262 | $2.9M | ||
| Q2 24 | $226 | $2.6M | ||
| Q1 24 | $50 | $4.5M |
| Q4 25 | $48.1M | $4.2M | ||
| Q3 25 | $50.7M | $3.5M | ||
| Q2 25 | $78.3M | $3.8M | ||
| Q1 25 | $81.8M | $5.5M | ||
| Q4 24 | $82.3M | $681.0K | ||
| Q3 24 | $82.9M | $-332.0K | ||
| Q2 24 | $83.2M | $-1.9M | ||
| Q1 24 | $83.6M | $-2.1M |
| Q4 25 | $57.8M | $30.2M | ||
| Q3 25 | $83.6M | $30.5M | ||
| Q2 25 | $149.7M | $32.3M | ||
| Q1 25 | $152.3M | $30.6M | ||
| Q4 24 | $150.1M | $25.2M | ||
| Q3 24 | $157.3K | $24.9M | ||
| Q2 24 | $159.8K | $26.1M | ||
| Q1 24 | $170.6K | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $-1.7M |
| Free Cash FlowOCF − Capex | $1.7M | $-2.0M |
| FCF MarginFCF / Revenue | 7.6% | -13.1% |
| Capex IntensityCapex / Revenue | 0.1% | 1.6% |
| Cash ConversionOCF / Net Profit | — | -6.47× |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0K | $5.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $-1.7M | ||
| Q3 25 | $-4.8M | $600.0K | ||
| Q2 25 | $2.2M | $6.9M | ||
| Q1 25 | $1.1M | $490.0K | ||
| Q4 24 | $3.2M | $-283.0K | ||
| Q3 24 | $6.5M | $311.0K | ||
| Q2 24 | $7.3M | $-1.8M | ||
| Q1 24 | $7.4M | $-919.0K |
| Q4 25 | $1.7M | $-2.0M | ||
| Q3 25 | $-4.9M | $554.0K | ||
| Q2 25 | $2.1M | $6.6M | ||
| Q1 25 | $1.0M | $448.0K | ||
| Q4 24 | $2.5M | $-377.0K | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $7.3M | $-1.8M | ||
| Q1 24 | $6.9M | $-1.0M |
| Q4 25 | 7.6% | -13.1% | ||
| Q3 25 | -18.1% | 4.0% | ||
| Q2 25 | 9.1% | 53.5% | ||
| Q1 25 | 5.0% | 2.6% | ||
| Q4 24 | 10.2% | -2.8% | ||
| Q3 24 | 21.7% | — | ||
| Q2 24 | 28.5% | -13.0% | ||
| Q1 24 | 28.1% | -8.4% |
| Q4 25 | 0.1% | 1.6% | ||
| Q3 25 | 0.4% | 0.3% | ||
| Q2 25 | 0.0% | 2.0% | ||
| Q1 25 | 0.1% | 0.2% | ||
| Q4 24 | 3.0% | 0.7% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 2.0% | 0.8% |
| Q4 25 | — | -6.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | -0.39× | ||
| Q3 24 | — | 0.24× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
